Drug Trial Radar · NCT00230971
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Last checked: Nov 19, 2026Latest source record: Feb 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
473
Actual
Start
Oct 2005
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 3, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).
Conditions
- Appendicitis
- Cholecystitis
- Diverticulitis
- Intra-Abdominal Abscess
- Intra-Abdominal Infection
- Peritonitis
Interventions
tigecyclineDrug
every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
ceftriaxone plus metronidazoleDrug
Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) VisitTime frame: up to 6 weeks
Locations
68 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Cairns, Australia
Site not named
Parkville, Australia
Site not named
Nambour, Queensland, Australia
Site not named
Shanghai, China
Site not named
Odense, Denmark
Site not named
Lahti, Finland
Site not named
Seinäjoki, Finland
Site not named
Tampere, Finland
Site not named
Marseille, France
Site not named
Nîmes, France
Site not named
Pierre-Bénite, France
Site not named
Saint-Denis, France
Site not named
Bochum, Germany
Site not named
Frankfurt, Germany
Site not named
Freiburg im Breisgau, Germany
Site not named
Heidelberg, Germany
Site not named
Leipzig, Germany
Site not named
Lübeck, Germany
Site not named
Münster, Germany
Site not named
Tübingen, Germany
Site not named
Athens, Greece
Site not named
Athens, Greece
Site not named
Thessaloniki, Greece
Site not named
New Territories, Hong Kong
Site not named
Pokfulam, Hong Kong
Site not named
Bhopal, India
Site not named
Lucknow, India
Site not named
Mumbai, India
Site not named
New Delhi, India
Site not named
Hyderabad, Telangana, India
Site not named
Brescia, Italy
Site not named
Genova, Italy
Site not named
Pavia, Italy
Site not named
Rome, Italy
Site not named
Udine, Italy
Site not named
Vicenza, Italy
Site not named
Manila, Philippines
Site not named
Quezon City, Philippines
Site not named
Quezon City, Philippines
Site not named
Almada, Portugal
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.